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Abstract
Research activity related to different aspects of prevention, prediction, diagnosis and treatment of brain metastases has
increased during recent years. One of the major databases (Scopus) contains 942 scientific articles that were published
during the 5-year time period 2006–2010. Of these, 195 (21%) reported on single patient cases and 12 (1%) were reports of 2
cases. Little is known about their influence on advancement of the field or scientific merits. Do brain metastases case reports
attract attention and provide stimuli for further research or do they go largely unrecognized? Different measures of impact,
visibility and quality of published research are available, each with its own pros and cons. For the present evaluation, article
citation rate was chosen. The median number of citations overall and stratified by year of publication was 0, except for the
year 2006 when it was 2. As compared to other articles, case reports remained more often without citation (p,0.05 except
for 2006 data). All case reports with 10 or more citations (n=6) reported on newly introduced anticancer drugs, which
commonly are prescribed to treat extracranial metastases, and the responses observed in single patients with brain
metastases. Average annual numbers of citations were also calculated. The articles with most citations per year were the
same six case reports mentioned above (the only ones that obtained more than 2.0 citations per year). Citations appeared to
gradually increase during the first two years after publication but remained on a generally low or modest level. It cannot be
excluded that case reports without citation provide interesting information to some clinicians or researchers. Apparently,
case reports describing unexpected therapeutic success gain more attention, at least in terms of citation, than others.
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Introduction
Development of brain metastases is a common problem in
oncology [1]. Given the large number of patients and important
consequences for individual patients and health care systems,
intense research activity is directed towards prevention and
therapy. Landmark phase III randomized trials, other prospective
studies, improved multidisciplinary interaction, and technology
improvement provided the framework for recent treatment
advances. If one looks at all scientific publications a broad mix
of prospective and retrospective studies, reviews, and case reports
can be identified. Intuitively, one would expect at best minor or
moderate influence of small retrospective studies or even case
reports on changes in clinical practice. However, little is known
about the actual attention that case reports receive after
publication and whether or not they are cited by other
publications. Measuring their impact is not trivial. Impact factor
of journals that publish case reports is a two-edged sword, e.g.
regarding its correlation with the true scientific or practical impact
of the reports [2–6]. Article download rates might provide some
indication for visibility and impact, but will depend on presence
and quantity of fees charged by the publisher. Another potential
measure of quality and impact of research is the citation rate [7–
10]. Landmark or practice-changing research is likely to be cited
by successor trials, editorials, review articles, meta-analyses and
guidelines. In our attempt to evaluate the role of case reports in
brain metastases therapy, including related areas of diagnostic and
prevention, we therefore relied on citation rates of such reports
that were published between 2006 and 2010. We hypothesized
that case reports might have accumulated fewer citations than
other articles.
Methods
A systematic search of the abstract and citation database Scopus
(Elsevier B.V., www.scopus.com) by use of the key words ‘brain
metastases’, ‘cerebral metastases’, ‘intracranial metastases’, ‘cen-
tral nervous system metastases’ or ‘secondary brain tumor’ was
performed on November 28
th and 29
th 2011. To begin with,
publications related to metastases from extracranial solid tumors in
pediatric and adult patients were selected irrespective of language
and article type (case report, review, randomized trial, meta-
analysis etc.). In other words, all epidemiologic, diagnostic,
therapeutic and preclinical topics published in the time period
2006–2010 were included. The issues of prophylactic cranial
irradiation and leptomeningeal carcinomatosis were not included
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parenchymal brain metastases. Articles dealing with brain
metastases and glioma, e.g. related to differential imaging
diagnosis, were included as well. Then, all case reports describing
one or two patients were extracted and patterns of citation (field
‘times cited’ in the Scopus database) were evaluated. Since the title
of an article might or might not indicate that one or two cases are
reported, we accessed abstracts or if necessary complete articles to
make sure that all eligible publications were included. We
evaluated median number of citations, proportion of case reports
without citation, total number of citations accumulated indepen-
dently of their origin, and average annual number of citations.
Statistical comparisons were performed with the Fisher exact
probability and Mann-Whitney U tests. A one-sided p-value,0.05
was considered statistically significant.
Results
Overall 942 brain metastases publications were identified (167–
226 per year). Of these, 195 (21%) reported on single patient cases
and 12 (1%) were reports of 2 cases (a complete list can be
requested from the corresponding author). Figure 1 shows the
numbers of publications per year. Overall, publication numbers
have increased in the time period 2006–2010. The proportion of
case reports remained constant. Table 1 shows the citation
patterns. The median number of citations of non-case-reports
published in a given year was lower in 2009 and 2010 as compared
to previous years. In other words, accumulation of citations takes
time. Case reports were cited less often. Their median number of
citations overall and stratified by year was 0, except for the year
2006. As compared to other articles, case reports remained more
often without citation (p,0.05, except for 2006 data). Table 2
shows the most cited case reports overall [11–16], arbitrarily
defined as 10 or more citations (n=6). All of these were published
in English language and reported on newly introduced anticancer
drugs, which commonly are prescribed to treat extracranial
metastases, and the responses observed in single patients with
brain metastases. All were published before 2009. Since articles
published for example in 2006 are more likely to have
accumulated a large number of citations than articles published
in 2010, average annual numbers of citations were also calculated.
For this purpose, 2011 was defined as 0.92 years (11 of 12 months;
January–November). The articles with most citations per year are
also shown in Table 2. They were identical to the 6 publications
with 10 or more citations and had 2.5–6.1 citations per year. All
others had less than 2.0 citations per year. Group authorship was
most common. Five case reports (2.4%) had one author, 12 (5.8%)
had two authors, 26 (12.6%) had 3 authors, 39 (18.9%) had four
authors, and the others (60.3%) had more than four authors.
Discussion
This analysis was based on a systematic literature search where
we decided to apply a broad definition of brain metastases related
publication. We acknowledge that some of the selected case
reports might be subject to debate. Moreover, we encourage
authors of relevant publications that might have been overlooked
to inform us about their article in order to refine future
evaluations. Reference [14] represents one of the case reports
with a title clearly indicating the type of publication. References
[13,15] provide examples for case reports that were more difficult
to identify at first glance. From our point of view, it would be
desirable that all case reports could be identified quickly and
easily. Journal editors and publishers should take responsibility in
providing unambiguous manuscript titles.
In general, the number of publications on brain metastases has
increased continuously (Figure 1). The number of case reports has
increased as well, while their proportion remained constant. In this
analysis, we focused on citation counts. Articles with high numbers
of citations are likely those that impressed other scientists and
clinicians, and had more influence on clinical practice or future
developments in the field than articles with few citations. However,
the majority of case reports published in the time period 2006–
Figure 1. Number of articles and case reports published per
year.
doi:10.1371/journal.pone.0034300.g001
Table 1. Citation patterns: Statistically significant differences between case reports (one patient) and other articles were seen
regarding median number (except for 2010 data) and percent without citation (except for 2006 data).
2006 2007 2008 2009 2010
Median number of total citations, range (other articles) 5, 0–282 5, 0–89 4, 0–108 3, 0–123 1, 0–42
Median number of total citations, range (case reports, one
patient)
2, 0–15 0, 0–30 0, 0–12 0, 0–4 0, 0–2
Median number of total citations, range (case reports, two
patients)
3, 0–4 1* 0* 0, 0–2 0, 0–2
Percent without citation (other articles) 20 23 27 26 40
Percent without citation (case reports, one patient) 27 52 51 61 68
Percent without citation (case reports, two patients) 33 0* 100* 67 75
*only one published article.
Because only 12 case reports on two patients were available, no statistical tests were performed for this subgroup.
doi:10.1371/journal.pone.0034300.t001
Brain Metastases Case Reports
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reporting on two cases received citation counts comparable to
those describing only one case. However, the number of articles
reporting on two cases was low. The maximum number of
citations was 30 as compared to 282 [17] for non-case-reports
published during the same time period. All case reports with 10 or
more citations were published in the English language and
reported on newly introduced anticancer drugs, which commonly
are prescribed to treat extracranial metastases, and the responses
observed in single patients with brain metastases. Even if none of
the drugs has become a standard of care for patients with brain
metastases by now, the initial observations made in these case
reports might trigger formal prospective studies or sometimes
provide clues towards a therapeutic option for heavily pretreated
patients when no more standard of care exists. Of course
publication bias must also be considered. One cannot exclude
that the same drug may have been tried in individual cases in lots
of different hospitals, but only the one successful attempt has
appeared in the literature. All case reports published in 2009 or
2010 consistently received less than 5 citations. Thus, our results
are consistent with the assumption that citation rate is gradually
increasing for approximately 2 years after publication. An earlier
study evaluated 2-year citation count of case reports published in
1991 and 2001 irrespective of topic [18]. The median citation
count was 0 and 1 for case reports published in 1991 and 2001,
respectively. Less than 1% received more than 10 citations within
2 years.
As stated previously, we also evaluated average annual citation
rate because the exact time course or kinetics of citation is hard to
predict and varies with topic and journal [19,20]. Both
accumulation of citations of recently published articles and
reduced interest in older articles over time pose challenges if
reliable quantitative analysis is attempted. We did not account for
date of publication, i.e. whether an article was published earlier or
later during a given year. For the purpose of this study, the chosen
methods are sufficient. Of course, more detailed and quantitative
analyses can be performed with the internet based tools available.
It should be noticed that searches in different databases will result
in somewhat different citation counts and that the present results
(based on Scopus) therefore provide only a snapshot. Self citation
is likely to influence the final citation count of sparsely cited
articles, whereas its impact on highly cited articles might be less
pronounced. It was recently estimated that 6.4% of all citations
per article (interquartile range 2.8–11.3, mean 8.4) were self
citations [21]. Studies most vulnerable to this effect were those
with more authors and small sample size. However, this study did
not focus on case reports.
In conclusion, research activity has increased in the time period
between 2006 and 2010 and case reports continue to contribute
approximately 20–21% of all publications. It cannot be excluded
that case reports without citation provide interesting information
to some clinicians or researchers, but their ultimate role is difficult
to quantify. Apparently, case reports describing unexpected
therapeutic success gain more attention, at least in terms of
citation, than others.
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